News

ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced the appointment of Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. “Buzz” Heidt Jr., who has served as Chairman since 2020, will continue to serve as a member of the Board of Directors.

“We are delighted to welcome Dr. Williams as Chairman of our Board of Directors,” said David Marek, Chief Executive Officer of ReAlta. “His exceptional track record in building successful biopharmaceutical companies and expertise in drug development will be invaluable as ReAlta advances its clinical programs.”

“I would like to welcome Rusty to ReAlta at this exciting time in the company’s evolution,” said Buzz Heidt, member of ReAlta’s Board of Directors. “Rusty brings a wealth of leadership experience and insight to ReAlta, and I am eager to work with him as our incoming Board Chairman.”

“On behalf of the entire Board,” said Mr. Marek, “I wish to extend our sincerest gratitude to Buzz Heidt for over four years of Board service to ReAlta. Buzz’s collaborative partnership in the boardroom and strong leadership has positioned ReAlta for long-term success and Rusty and I look forward to his continued contributions as a Board member.”

“ReAlta is taking an innovative approach to address inflammation – the key driver of diseases across a wide spectrum of therapeutic areas. The unique ability of ReAlta’s dual-targeting EPICC peptides to address the earliest stages of the inflammatory cascade holds promise for treating inflammatory diseases successfully in ways existing therapies have been unable to,” said Dr. Williams. “I look forward to working closely with the Board Directors and management team to help realize the full potential of ReAlta’s technology to benefit patients with severe inflammatory diseases who currently have limited therapeutic options.”

Learn more here. 

Recent News

05/13/2026

BRAINBox Solutions Announces Appointment of Richard H. Noel as Chief Product and Commercial Officer

BRAINBox Solutions today announced the appointment of Richard H. Noel to the newly created position of Chief Product and Commercial Officer. Richard brings more than 10 years of experience in molecular and point-of-care diagnostics, at Roche Diagnostics, LumiraDx, and bioMérieux. “Richard, whose expertise spans market analytics, global product management, and senior commercial leadership, has established

05/12/2026

Phlow Corp. Appoints Tim Mayleben Chief Executive Officer as Co-Founder Dr. Eric Edwards Transitions to Chairman Emeritus and Strategic Advisor

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Tim Mayleben has been appointed Chief Executive Officer, effective immediately. Eric Edwards, M.D., Ph.D., Phlow’s co-founder and former CEO, has transitioned to the role of Chairman Emeritus and Strategic Advisor to the CEO and Board of Directors. The leadership

05/09/2026

NIRSense Supports the US Army in the Indo-Pacific with Tissue Oxygenation Assessment for Battlefield Casualty Care at Balikatan-26

NIRSense, Inc. today announced its participation in Balikatan-26, supporting the US Army Pacific (USARPAC)’s 18th Theater Medical Command (18th TMC) as they evaluate advanced approaches to battlefield casualty assessment using portable tissue oxygen saturation (StO₂) monitoring. Balikatan, meaning “shoulder-to-shoulder,” is the longstanding U.S.-Philippine bilateral exercise designed to strengthen interoperability and regional readiness through combined operations